Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: bio_kruncher who wrote (20082)	8/25/2006 11:56:13 AM
From: Biomaven	Read Replies (3) \| Respond to of 52153

biokruncher, Do you have any idea why THRX in the Telavancin trial (which had co-endpoints of non-inferiority in the whole trial and superiority in the MRSA subset) would have been required to use a .025 p value (one-sided) for the superiority analysis? In case you haven't been following the trial, they met the non-inferiority endpoint, but missed the other with a p value just north of .05 So all-in-all a very good result, expecially as vanco (the comparator) did very well. Peter